Navigation Links
inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007
Date:2/28/2008

Reconfirms Revenue and Earnings Guidance for 2008 - Total Revenues Up 28% to $977.3mm for Full Year; Up 27% to $268.0mm for

Fourth Quarter - Adjusted EPS (incl. Stock Compensation) Up 16% to $1.59 for Full Year (GAAP EPS down 11% to $1.46); Up 27% to $0.47 for Fourth Quarter (GAAP EPS

up 62% to $0.47) - Continuing New Win Momentum and Pipeline Strengthening Across Segments - Reconfirming 2008 Revenue Guidance of $1.05 - $1.15 billion and Adjusted

EPS Guidance of $1.80 - $1.90 including Stock Compensation (GAAP EPS

Guidance of $1.78 - $1.88) See note (1) below for an explanation of all non-GAAP financial measures.

All segment information is presented on a comparable basis as if the

Company had operated with four segments since inception.

SOMERSET, N.J., Feb. 28 /PRNewswire-FirstCall/ -- inVentiv Health, Inc. (Nasdaq: VTIV), a leading provider of commercialization services to the global pharmaceutical and healthcare industries, today announced record financial results for the fourth quarter and full year 2007.

Fourth Quarter 2007 Results from Continuing Operations:

-- Total revenues increased 27% to $268.0 million for the fourth quarter

of 2007, compared to $211.8 million for the fourth quarter of 2006.

Net revenues increased 26% to $214.2 million, compared to $170.3

million for the fourth quarter of 2006.

-- Adjusted operating income increased 43% to $31.5 million for the fourth

quarter of 2007, compared to $22.0 million for the fourth quarter of

2006. GAAP operating income increased 75% to $32.3 million for the

fourth quat of accounting rules or principles. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with the Company's results of operations as determined in accordance with GAAP and these measures should only be used to evaluate the Company's results of operations in conjunction with the corresponding GAAP measures. Management believes that the non-GAAP financial measures included in the exhibit, when shown in conjunction with the corresponding GAAP measures, is useful to investors for the reasons discussed above. Management uses these non-GAAP financial measures in assessing the performance of the Company's operations on a consistent basis from period to period.

Forward-Looking Information

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by inVentiv Health, Inc. with the Securities and Exchange Commission for further discussion of these and other factors.

inVentiv Health, Inc.

CONSOLIDATED INCOME STATEMENTS

(in thousands, except per share amounts)

For the Three- For the Twelve-

Months Ended Months Ended

December 31, December 31,

2007 2006 2007 2006

Net revenues $214,163 $170,260 $796,659 $631,620

Reimbursable out-of-pockets 53,834 41,548 180,641 134,625

Total revenues 267,997 211,808 977,300 766,245

Operating expenses:

Cost of services 126,631 110,512 498,106 410,184

Reimbursed out-of-pocket

expenses 54,677 42,161 183,456 136,565

Selling, general and

administrative expenses 54,400 40,609 200,945 141,418

Total operating expenses 235,708 193,282 882,507 688,167

Operating income 32,289 18,526 94,793 78,078

Interest expense (6,696) (3,607) (20,717) (11,361)

Interest income 971 914 3,039 2,694

Income from continuing

operations before income tax

provision, minority interest

in income of subsidiary and

income from equity

investments 26,564 15,833 77,115 69,411

Income tax provision (10,831) (6,561) (29,401) (19,166)

Income from continuing

operations before minority

interest in income of

subsidiary and income from

equity investments 15,733 9,272 47,714 50,245

Minority interest in income

of subsidiary (335) (302) (1,070) (1,207)

Income from equity

investments 144 27 582 160

Income from continuing 15,542 8,997 47,226 49,198

operations

Income from discontinued

operations:

(Losses) gains on disposals

of discontinued operations,

net of taxes (9) 768 258 2,037

(Loss) income from

discontinued operations (9) 768 258 2,037

Net income $15,533 $9,765 $47,484 $51,235

Earnings per share:

Continuing operations:

Basic $0.48 $0.30 $1.50 $1.69

Diluted $0.47 $0.29 $1.46 $1.64

Discontinued operations:

Basic $0.00 $0.03 $0.00 $0.07

Diluted $0.00 $0.03 $0.01 $0.06

Net income:

Basic $0.48 $0.33 $1.50 $1.76

Diluted $0.47 $0.32 $1.47 $1.70

Weighted average common

shares outstanding:

Basic 32,309 29,816 31,578 29,159

Diluted 32,871 30,596 32,267 30,058

inVentiv Health, Inc.

Selected Financial Data

($'s in 000's)

(unaudited)

December 31, December 31,

2007 2006

Cash $50,973 $79,835

Restricted Cash and Marketable Securities $47,164 $50

Account Receivable, Net $162,198 $124,283

Unbilled Services $89,384 $75,691

Total assets $1,110,856 $771,054

Client Advances & Unearned Revenue $76,696 $64,508

Working Capital (1) $130,852 $86,684

Long-term debt (2) $328,350 $164,584

Capital Lease Obligations (2) $38,409 $33,508

Depreciation (3) $18,169 $15,130

Amortization (3) $10,939 $5,610

Days Sales Outstanding (4) 79 73

(1) Working Capital is defined as total current assets less total current

liabilities.

(2) Liabilities are both current and noncurrent.

(3) Depreciation and amortization are reported on a year-to-date basis.

(4) Days Sales Outstanding ("DSO") is measured using the combined amounts

of Accounts Receivable and Unbilled Services (excluding work-in-

progress, which does not affect calculation) outstanding as of the

Balance Sheet date, against Revenues for the trailing 3-month period

then ended. The calculation excludes acquisitions made during the

fourth quarter of 2006 and 2007.

inVentiv Health, Inc.

Non-GAAP Income Statement Reconciliation

For the Three and Twelve Months Ended December 31, 2007 and 2006

(unaudited)

Reconciliation of Operating Income Three-Months Twelve-Months

(in millions) Ended December 31, Ended December 31,

(Subtract) Add 2007 2006 2007 2006

Operating income, as reported $32.3 $18.5 $94.8 $78.1

Receivables reserve (0.1) -- 8.1 --

Other than temporary impairment

on marketable securities 0.8 -- 0.8 --

Acquisition-related incentive (1.5) 3.5 (1.5) 3.5

Operating income, as adjusted $31.5 $22.0 $102.2 $81.6

Reconciliation of Income from

Continuing Operations Three-Months Twelve-Months

(in millions) Ended December 31, Ended December 31,

(Subtract) Add 2007 2006 2007 2006

Income from continuing

operations, as reported $15.5 $9.0 $47.2 $49.2

Receivables reserve, net of taxes -- -- 4.8 --

Other than temporary impairment

on marketable securities, net of taxes 0.5 -- 0.5 --

Acquisition-related incentive,

net of taxes (0.9) 2.1 (0.9) 2.1

Derivative interest, net of taxes 0.2 0.2 0.7 (1.2)

Deduct: Tax benefit -- -- (1.0) (9.1)

Income from continuing

operations, as adjusted $15.3 $11.3 $51.3 $41.0

Three-Months Twelve-Months

Reconciliation of Earnings per Share Ended December 31, Ended December 31,

(Subtract) Add 2007 2006 2007 2006

Diluted earnings per share from

continuing operations, as reported $0.47 $0.29 $1.46 $1.64

Receivables reserve -- -- 0.15 --

Other than temporary impairment

on marketable securities 0.02 -- 0.02

Acquisition-related incentive (0.03) 0.07 (0.03) 0.07

Derivative interest, net of taxes 0.01 0.01 0.02 (0.04)

Tax benefits -- -- (0.03) (0.30)

Diluted earnings per share from

continuing operations, as adjusted $0.47 $0.37 $1.59 $1.37

2008 Guidance Update Reconciliation (unaudited)

Guidance

2008

Diluted earnings per share from

continuing operations $1.78 - $1.88

Derivative interest, net of taxes 0.02

Diluted earnings per share from

continuing operations, as adjusted $1.80 - $1.90

Twelve- Months

Proforma Growth Rate on a Net Revenue Basis Ended December 31,

(unaudited) 2007 vs 2006

Growth rate, as reported 26%

Less: Acquisition Growth Rate (13%)

Growth rate, proforma 13%

rter of 2007, compared to $18.5 million for the fourth

quarter of 2006.

-- Adjusted income from continuing operations increased 35% to $15.3

million for the fourth quarter of 2007, compared to $11.3 million for

the fourth quarter of 2006. GAAP income from continuing operations

increased 72% to $15.5 million for the fourth quarter of 2007, compared

to $9.0 million for the fourth quarter of 2006.

-- Adjusted diluted earnings per share (EPS), including stock compensation

expense, increased 27% to $0.47 for the fourth quarter of 2007,

compared to $0.37 for the fourth quarter of 2006. GAAP diluted EPS

increased 62% to $0.47 for the fourth quarter of 2007, compared to

$0.29 for the fourth quarter of 2006.

Full Year 2007 Results from Continuing Operations:

-- Total revenues increased 28% to $977.3 million for 2007, compared to

$766.2 million for 2006. Net revenues increased 26% to $796.7 million,

compared to $631.6 million for 2006. Pro-forma organic net revenue

growth for 2007 was 13% compared to the same period last year.

-- Adjusted operating income increased 25% to $102.2 million for 2007,

compared to $81.6 million for 2006. GAAP operating income increased

21% to $94.8 million for 2007, compared to $78.1 million for 2006.

-- Adjusted income from continuing operations increased 25% to $51.3

million for 2007, compared to $41.0 million for 2006. GAAP income from

continuing operations decreased 4% to $47.2 million for 2007, compared

to $49.2 million for 2006. This decrease is reflective of the $1.0

million and $9.1 million of tax benefits recognized in 2007 and 2006,

respectively, as described in note (1).

-- Adjusted diluted EPS, including stock compensation expense, increased

16% to $1.59 for 2007, compared to $1.37 for 2006. GAAP diluted EPS

decreased 11% to $1.46 for 2007, compared to $1.64 for 2006. This

decrease is reflective of $0.03 and $0.30 of tax benefits recognized in

2007 and 2006, respectively, as described in note (1).

2007 Highlights and Key Accomplishments:

-- Record Revenue, Adjusted Operating Income and Adjusted EPS: Total

revenue, adjusted operating income and adjusted EPS of $977.3 million,

$102.2 million and $1.59, respectively, were new records for inVentiv,

underscoring the strength of the Company's multi-faceted business model

and continued effective execution across its businesses. In addition,

inVentiv delivered 13% pro forma organic net revenue growth for the

year.

-- inVentiv Clinical reported record total revenues of $186.9 million

during 2007 and $47.9 million during the fourth quarter of 2007, up 25%

and 23% respectively from the comparable prior-year periods. Billable

headcounts in clinical staffing continued to increase meaningfully

during 2007, further strengthening inVentiv Clinical's market position

in an expanding clinical trials marketplace. Revenues also increased

significantly within inVentiv Clinical's functional outsourcing

business.

-- inVentiv Communications reported record total revenues of $289.1

million during 2007 and $88.1 million during the fourth quarter of

2007, up 39% and 53% respectively from the comparable prior-year

periods, including results from several acquisitions completed during

2007. The division delivered over 30 significant new wins or

expansions with existing accounts over the course of the year,

resulting in enhanced momentum in the fourth quarter of 2007 and

accelerating organic growth leading to a strengthened outlook for 2008.

-- inVentiv Commercial reported total revenues of $400.8 million during

2007 and $100.8 million during the fourth quarter of 2007, up 15% and

5% respectively from the comparable prior-year periods, including the

wind-down of its Novartis contract in the fourth quarter. The division

finished 2007 with several new sales team wins and expansions including

two contracts with mid-tier pharma clients, an agreement with a leading

biotechnology company, the continued expansion of its two new 'on-

boarding' programs, and new wins and project expansions in various

specialty services for more than 40 clients.

-- inVentiv Patient Outcomes, the Company's newest segment, reported

record total revenues of $100.5 million during 2007 and $31.3 million

during the fourth quarter of 2007, up 62% and 59% respectively from the

comparable prior-year periods. This strong performance included

several new wins in the patient compliance and nurse educator

businesses, as well as the results from AWAC, which was acquired in

July 2007.

-- Strategic Acquisitions: During 2007 inVentiv strengthened its

Communications segment with the addition of Chandler Chicco Agency,

Chamberlain Healthcare Public Relations, Ignite Health and Addison-

Whitney, bolstered its Commercial segment with the addition of

Strategyx, and formed inVentiv Patient Outcomes in conjunction with the

acquisition of AWAC. At the end of the fourth quarter of 2007,

inVentiv also increased its equity stake in its Germany affiliate

Liedler GmbH.

-- Strong Win Momentum: inVentiv added over 125 net new clients and now

serves over 325 unique clients and supports over 850 client brands. In

addition, inVentiv delivered over 130 cross-business unit new pitches

in 2007, and is actively pursuing a new business pipeline of over $400

million.

-- Key Investments: The Company significantly strengthened its senior

management team in 2007 with the promotion of R. Blane Walter to

President, Terrell G. Herring to Chief Operating Officer and other key

leadership appointments. In addition, in late 2007 inVentiv initiated

several key new investments, primarily in technology in its Clinical

segment and in integrated account management, in order to further drive

longer-term growth and margin expansion.

-- Strong Cash Flow: As a result of the strength of inVentiv's

operations, the Company generated $58.7 million of cash flow from

operations during 2007, including $43.2 million in the fourth quarter,

and finished the year with $98.1 million of cash and marketable

securities on the balance sheet as of December 31, 2007.

Mr. Eran Broshy, Chairman and Chief Executive Officer of inVentiv Health, commented, "I am very pleased with inVentiv's record fourth quarter and full year results, demonstrating our unique leadership position built on a strong and diversified business model. We have continued to effectively execute for our clients by offering best-in-class offerings, and also are increasingly delivering broader integrated solutions to our clients. At the same time, I am excited at our increasing new win momentum and the significant new business pipeline we are pursuing, which now stands at over $400 million."

2008 Guidance Reconfirmed

Based on the Company's strong performance during the fourth quarter and full year of 2007, the Company is, at this time, reconfirming its 2008 revenue guidance of $1.05 - $1.15 billion and adjusted earnings per share guidance of $1.80 - $1.90 including stock compensation expense (GAAP earnings per share guidance of $1.78 - $1.88).

Adjusted guidance figures exclude derivative interest income or expense related to the Company's interest rate hedge on its term loan facility, certain impairment charges from marketable securities, and non-recurring tax adjustments.

Conference Call Information

Thursday, February 28, 2008, 9:00 a.m. Eastern Time

Call in number: (800) 358-8448 (Domestic) or (706) 634 1367(International)

Live and archived webcast: http://www.inventivhealth.com

A replay of the call will be available immediately following the call through March 6, 2008 at (800) 642-1687 or (706) 645-9291. The conference ID number for the replay is 32253136.

In concert with the call, information regarding inVentiv Health's historical and recent operational and financial performance will be available at http://www.inVentivHealth.com/health/investorRelations/investorDecks.asp.

About inVentiv Health

inVentiv Health, Inc. (Nasdaq: VTIV) is an insights-driven global healthcare leader that provides dynamic solutions to deliver customer and patient success. inVentiv delivers its customized clinical, sales, marketing and communications solutions through its four core business segments: inVentiv Clinical, inVentiv Communications, inVentiv Commercial, and inVentiv Patient Outcomes. inVentiv Health's client roster is comprised of more than 325 leading pharmaceutical, biotech, life sciences and healthcare payor companies, including all top 20 global pharmaceutical manufacturers. For more information, visit http://www.inVentivHealth.com.

(1) USE OF NON-GAAP FINANCIAL MEASURES

This press release contains non-GAAP financial measures which is intended to make the Company's financial statements more directly comparable on a period-to-period basis. The Company's objectives in presenting non-GAAP financial measures are:

-- To present the financial statements on a more comparable period-to-

period basis;

-- To enhance investors' overall understanding of the Company's past

financial performance and its planning and forecasting of future

periods; and

-- To allow investors to assess the Company's financial performance using

management's analytical approach.

Table 3 below contains reconciliations of the non-GAAP financial measures contained in this press release to the most directly comparable GAAP financial measures.

The "adjusted" non-GAAP financial measures discussed in this press release is related to the following five factors:

-- Receivable reserve: During the second quarter of 2007, the Company

recorded additional reserves for receivables and other related expense

of $8.2 million ($4.8 million net of taxes), of which $0.1 million

(negligible, net of taxes) was reversed during the fourth quarter of

2007, mainly relating to a collections issue due to the bankruptcy of

one of its clients within the Commercial segment. Historical write-

offs have been minimal and the Company does not believe there is a

significant risk that the circumstances giving rise to these additional

reserves will recur in future periods. The 2007 full year results were

adjusted to exclude the recording and reversals of these receivable

reserves.

-- Other than Temporary Impairment on Marketable Securities: During the

fourth quarter of 2007, the Company recorded $0.8 million ($0.5 million

net of taxes) related to an other than temporary impairment of the

Company's Columbia Strategic Cash Portfolio ("CSCP"), which held

certain asset-backed securities. Consistent with the company's

investment policy guidelines, the vast majority of holdings within CSCP

held by the company had AAA/Aaa credit ratings at the time of purchase.

With the liquidity issues experienced in the global credit and capital

markets, the CSCP experienced other than temporary losses resulting in

a change in the net asset value per share from its $1 par value. The

other than temporary impairment loss was adjusted to exclude this

charge for fourth quarter and full year 2007 results.

-- Acquisition-related incentive: The fourth quarter and full-year

periods for 2007 and 2006 exclude $1.5 million of income and $3.5

million of expense, respectively, of acquisition-related incentives

arising from a pre-acquisition liability related to the acquisition of

inVentiv Communications, Inc. (the former "inChord Communications").

In connection with the inVentiv Communications, Inc. acquisition, the

Company assumed a $7.5 million existing liability (out of a potential

$15.0 million liability) on inVentiv Communications, Inc.'s balance

sheet relating to certain performance thresholds over a three-year

period from 2005 through 2007. The Company has monitored these

performance thresholds on a quarterly basis, and as of December 31,

2006, $3.5 million of additional non-recurring expense was recorded as

a result of management's evaluation of new business wins during 2006

and the strengthened outlook for inVentiv Communications, Inc.'s

business during 2007. Based on the final 2005-2007 three-year

performance results of inVentiv Communications, Inc., a reversal of

$1.5 million was recorded to this liability and as additional income in

2007. The acquisition-related incentives were adjusted to exclude these

adjustments in their respective periods.

-- Derivative Interest: In October 2005, the Company engaged in an

interest rate hedge of its $175 million term loan facility, which the

Company did not designate for hedge accounting until July 2006. In

July 2006, the Company employed a hypothetical derivative model to

assess ineffectiveness. For the three-months ended December 31, 2007

and 2006, the Company recorded $0.3 million of interest expense ($0.2

million net of taxes) relating to the ineffectiveness of the hedge for

each quarter. For the twelve-months ended December 31, 2007 and 2006,

the Company recorded $1.2 million and $2.1 million of interest expense

and interest income ($0.7 million of interest expense and $1.2 million

of interest income, net of taxes), respectively, relating to the

ineffectiveness of the hedge for each period. Net interest expense was

adjusted to exclude these adjustments in their respective periods.

-- Tax benefits: The Company recorded federal tax benefits of $1.0

million in the first quarter of 2007 attributable to related state and

local tax exposure and $9.1 million in the second quarter of 2006

related to the utilization of net operating losses of divested

entities. Tax expense was adjusted to exclude these benefits for full

year 2007 and 2006.

In addition, this press release contains non-GAAP financial measures related to the pro-forma organic net revenue growth rate for 2007. This growth rate is calculated as if all companies acquired by the Company as of December 31, 2007 were owned by it as of January 1, 2006.

These non-GAAP measures are not in accordance with, or an alternative for, generally accepted accounting principles and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive se
'/>"/>

SOURCE inVentiv Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. inVentiv Health Ranked #17 by Training Magazine in its 2008 List of Top 125 Training Companies
2. inVentiv Health to Announce Fourth Quarter and Full Year 2007 Results and Conduct Conference Call on Thursday, February 28th
3. inVentiv Health Provides Updated Information on December 11th Investor Day
4. inVentiv Health Creates Client Development and Integration Team
5. inVentiv Health to Present at the 2007 Credit Suisse Healthcare Conference
6. inVentiv Health Launches Fourth Business Segment: inVentiv Patient Outcomes
7. inVentiv Health to Announce Third Quarter Results and Conduct Conference Call on Wednesday, November 7, 2007
8. inVentiv Health to Present at the 20th Annual Bear Stearns Healthcare Conference
9. Crdentia Selected by Leading Staffing Vendor to Provide Health Care Staffing Services to One of the Largest Hospital Chains in the U.S.
10. Former Blue Cross/Blue Shield Account Manager Sentenced for Health Care Fraud Scheme, Tax Evasion
11. UCLA launches network to study health care disparities affecting minorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... ... Boston Children’s Hospital today announced its new pediatric Simulation (SIM) Center — ... procedures in an environment that looks and feels real. , Located in the heart ... “hackers” to develop and test new devices or software platforms and see how they ...
(Date:5/3/2016)... Dallas, Texas (PRWEB) , ... May 03, 2016 , ... ... that live in or adjacent to the 75204, 75205, 75206, 75209, 75219, 75220, ... Oak Lawn/Uptown, Greenway Parks, Bluffview, Midway Hollow, North Dallas, Plano, Preston Hollow and Park ...
(Date:5/3/2016)... ... May 03, 2016 , ... Intrigma, the leading ... Legacy Health is expanding its use of Intrigma’s cloud-based physician scheduling solution, Efficient ... proof of concept. The Portland, Oregon based health system conducted a one-year pilot ...
(Date:5/3/2016)... ... May 03, 2016 , ... Dr. Poneh Ghasri, cosmetic dentist ... to both new and existing patients. Cosmetic dentistry allows patients to improve the aesthetics ... healthy smiles with some minor or more serious cosmetic flaws. These specials allow patients ...
(Date:5/3/2016)... ... 03, 2016 , ... Branches, Inc. is proud to have been selected as ... programs in South Miami. Macy’s is a wonderful community partner and has helped to ... tutoring, mentoring, enrichment and academic support to elementary students 5 days a week. Summer ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... 2, 2016 The global  ... 11.1 billion by 2024, according to a new ... drivers of the sonography market include expanding applications ... recommendations for periodic ultrasound screenings of the breast ... http://photos.prnewswire.com/prnh/20150105/723757 ) High Intensity Focused ...
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
(Date:4/28/2016)... April 28, 2016  Marking its one year ... and ovarian cancer risk test, Color Genomics ... genes that highly impact the most common hereditary ... the Color Test analyzes hereditary cancer risks for ... uterine cancers. The Color Test is physician ordered ...
Breaking Medicine Technology: